2024 Agenda


*All times are in EST


Fri 19

8:00AM -8:05AM

Introduction & Meeting Objectives
Co-chairs: David Maloney & Sarah Nikiforow

8:05AM -8:55AM

Session 1:  Emerging CARs and future challenges in solid tumors
Chairs: David Maloney & Maria Pia Morelli 

  • New solid tumor targets and engineering strategies for CAR-T: Justus Weber
  • Sleeping Beauty Therapy TCR-T Therapy in solid tumors: Maria Pia Morelli
  • Understanding mechanisms of immune resistance and developing strategies to overcome them: Smita Chandran

Panel discussion

8:55AM -9:20AM

Keynote talk: Review of results from CAR-T and TCRs in solid tumors: Julian Molina

Panel discussion

9:20AM -10:20AM

Session 2: Head & neck/brain tumors
Chairs: Kedar Kirtane & Susanne Baumeister

  • Updates in cellular immunotherapy for head & neck cancers: Kedar Kirtane
  • ALK-CAR T-cells for R/R neuroblastoma: Susanne Baumeister
  • GD2-CART01 for R/R high-risk neuroblastoma: Francesca del Bufalo
  • TanCART, novel CAR T-cell that simultaneously targets EGFRvIII and IL-13Rα2: Bryan Choi

Panel discussion

10:20AM -10:40AM


10:40AM -11:30AM

Session 3: CAR-T clinical advances in lung cancer
Chairs:  Prasad Adusumilli & Julian Molina

  • Updates on TIL therapy in lung cancer: Ben Creelan
  • Tumor immune modulation in solid tumor CAR T-cell therapy: Prasad Adusumilli
  • LL3-directed CAR T-cells in small-cell lung cancer: Adam Schoenfeld

Panel discussion

11:30AM -12:30PM

Session 4: Breast cancer and ovarian cancer
Chairs: Jennifer Specht & Smita Chandran

  • LYL797 in adults with solid tumors: Jennifer Specht
  • TCR-based therapeutics that target an elite class of common and shared tumor targets called ‘public neoantigens’: Smita Chandran
  • Intratumoral Delivery of Dendritic Cell-based Immunotherapies: Potential to Unlock Systemic anti-tumor Response in Breast Cancer: Saurabh Garg
  • Engineering NK cells for ovarian cancer: Rizwan Romee

Panel discussion

12:30PM -1:30PM


1:30PM -2:20PM

Session 5: Melanoma and sarcomas
Chairs: Amod Sarnaik & Allison Betof Warner 

  • Autologous tumor infiltrating lymphocytes, in the treatment of patients with metastatic melanoma (LN-144): Amod Sarnaik
  • TIL therapy for melanoma – have we reached the tip of the Iceberg?: Allison Betof Warner
  • Afamitresgene Autoleucel in advanced synovial sarcoma and myxoid/round cell liposarcoma: Elizabeth Loggers

Panel discussion

2:20PM -3:00PM

Session 6: Logistics and manufacturing
Chairs: David Maloney & Sarah Nikiforow

  • Manufacturing/FACT and ASTCT 80/20: Sarah Nikiforow
  • Biomarker-driven trials: William Go

Panel discussion

3:00PM -3:20PM


3:20PM -3:50PM

Keynote talk: An FDA perspective on CAR-T/cellular therapies in cancer: Asha Das

Panel discussion

3:50PM -4:30PM

Session 7: Gastrointestinal cancers
Chairs: Diane Simeone & Joel Randolph Hecht

  • CAR-T advances in pancreatic cancer: Diane Simeone
  • Autologous TAC T-cells targeting solid tumors, HER2 and Claudin18.2: Benjamin Schlechter
  • T-cell therapy for GI tumors: Joel Randolph Hecht

Panel discussion

4:30PM -5:20PM

Session 8: Genitourinary cancers
Chairs: Vivek Narayan & TBC

  • Bispecific antibodies and CAR-T approaches in metastatic castration-resistant prostate cancer: Vivek Narayan
  • Advancing engineered T-cell therapies for solid tumors: Saul Priceman
  • TILs treatment in bladder cancers: Michael Poch

Panel discussion

5:20PM -5:30PM

Conclusions & end of Day 1

6:30PM -8:30PM

Welcome reception


Sat 20

8:00AM -8:05AM

Co-chairs: John Gribben & David Maloney

8:05AM -8:45AM

Session 9: Scientific challenges and new approaches
Chairs: TBC

  • CD83 as a target for hematologic malignancies: Marco Davila
  • Towards in vivo manufacturing of CAR-T – updates and perspectives: Saar Gill

Panel discussion

8:45AM -9:55AM

Session 10: Long term toxicities of CAR T-cell therapy
Chairs: TBC

  • Hematologic toxicity (“ICAHT”): Kai Rejeski
  • Evolving neuro-toxicities and new treatment approaches: Bianca Santomasso
  • Secondary malignancies: Saurabh Dahiya
  • Cause of non-relapse mortality following Auto HCT, CAR19 or T-cell engagers: David Miklos
  • New data on TCL after CAR-T: David Hamilton

Panel discussion


9:55AM -10:15AM


10:15AM -10:55AM

Session 11: Access and Point of Care in Pediatric Cancer
Chairs: Rebecca Gardner & Shannon Maude

  • Accelerating pediatric CAR T-cell progress – decentralized academic manufacturing for expanded access: Claudia Rössig
  • CAR-pooling – innovative strategies in pediatric CAR T-cell development: Nirali Shah
10:55AM -11:25AM

Keynote talk: An FDA perspective on CAR-T/cellular therapies in blood cancers: Robert Sokolic

Panel discussion

11:25AM -12:25PM

Session 12: CAR-T in CLL
Chairs: Tanya Siddiqi & David Maloney

  • Update on TRANSCEND – liso-cel in CLL/SLL: Tanya Siddiqi
  • Mechanisms of resistance to CAR T-cells in CLL: Saar Gill

Panel discussion

12:25PM -1:25PM


1:25PM -2:55PM

Session 13: Allo approaches
Chairs: Caron Jacobson & Sattva Neelapu

  • Next-gen allo approaches/ donor T-cell cloaking to avoid host rejection: Sattva Neelapu
  • Updates for ALLO-647/501 in r/r large B-cell and follicular lymphomas: Frederick Locke
  • Updates for Allo CAR-T PBCAR0191: Bijal Shah
  • CRISPR-edited allogeneic anti-CD19 CAR T-cell therapy for R/​R B-cell NHL: Loretta Nastoupil
  • Allogeneic CAR-NK cells in adults with AML or MDS: May Daher
  • iPSC-derived CAR-NK: Krish Patel

Panel discussion

2:45PM -4:05PM

Session 14CAR-T in ALL
Chairs: Noelle Frey & Bijal Shah

  • Brexucabtagene autoleucel for adult ALL: Bijal Shah
  • Obe-cel updates and future directions: Claire Roddie
  • Dual-targeting with CAR-Ts: Regina Myers
  • Anti-CD7 Allogeneic CAR T-cells in Relapsed or Refractory (R/R) T-cell T-ALL/LBL: Shannon Maude
  • SCRI-CAR19 with CD19 T-APC to prolong CAR T-cell persistence: Rebecca Gardner

Panel discussion

4:05PM -4:25PM


4:25PM -5:15PM

Session 15: CAR-T in multiple myeloma
Chairs: Yi Lin & Krina Patel

How are T-cell-directed therapies performing in the real world?

  • CAR-T: Doris Hansen
  • BsAb: Yi Lin

Panel discussion: Susan Bal, Larry Anderson

Race to the front-line

  • CAR-T: Krina Patel
  • BsAb: Larry Anderson

Panel discussion: Sridevi Rajeeve, Damien Green

5:15PM -5:55PM

Session 16: CAR-T in multiple myeloma continued

Mechanisms of resistance

  • CAR-T: Damien Green
  • BsAb: Adam Sperling

Panel discussion: Matthew Frigault

5:55PM -6:10PM

Session 17: Novel CAR-T/next-gen BsAb
Chairs: Yi Lin & Krina Patel 

  • BCMA-directed CAR T-cell therapy anitocabtagene autoleucel: Matthew Frigault
  • BCMA/CD19 FastCART: Juan Du
  • Updates for GPRC5D CARs in multiple myeloma: Susan Bal
  • New BsAb research and opportunities in myeloma: Sridevi Rajeeve
  • Tri-specific T-cell activating construct (TriTAC) targeting BCMA for R/R myeloma: Sumit Madan

Panel discussion

6:10PM -6:15PM

Conclusions & end of Day 2

Faculty Dinner


Sun 21

8:00AM -8:05AM


8:05AM -9:20AM

Session 18: Special Sessions – CAR T-cells for autoimmune diseases
Chairs: David Porter & TBC

  • Advances in CAR-T for Auto-immune Diseases: David Porter
  • YTB323 in severe, refractory systemic lupus erythematosus: Pere Barba
  • NK cells engineered to target CD19 Programme in autoimmune diseases: David Shook
  • Anti-CD19 CAR T-cell therapy (KYV-101), in Subjects With Refractory Generalized Myasthenia Gravis: Jeremias Motte
  • CAR-Tregs for autoimmunity: Matteo Doglio

Panel discussion

9:20AM -10:20AM

Session 19: Expanding the CAR platform for NHL
Chairs: Loretta Nastoupil & Caron Jacobson

  • Long-term lymphoma outcomes following CAR T-cell therapy – where are we?: Michael Jain
  • ZUMA 22 and ZUMA 23 axi-cel updates: Caron Jacobson
  • New data in Liso cel – FL/MZL and MCL: Jeremy Abramson
  • QoL – late effects – why are our patients dying?: David Maloney

Panel discussion

10:20AM -10:40AM


10:40AM -11:35AM

Session 20: Bispecifics
Chairs: Loretta Nastoupil & Caron Jacobson

  • RWD and trials in progress for Epcoritamab: Krish Patel
  • Glofitamab RWD and trials in progress: Tycel Phillips
  • Total therapy for LBCL combining Mosun/Pola/Axi-cel: Jay Spiegel
  • Optimizing treatment through BsAbs sequencing: Gloria Iacoboni

Panel discussion

11:35AM -12:35PM

Session 21: Next generation CARs for lymphoma
Chairs: Loretta Nastoupil & Caron Jacobson                                                                                                                                                      

  • CRG-022, CD22 CAR T-cell therapy for R/R LBCL after CD19 CAR-T: Caron Jacobson
  • Bispecific CAR20.19 T-cells in MCL: Nirav Shah
  • CD20-targeted auto CAR-T for follicular lymphoma: Mazyar Shadman

Panel discussion

12:35PM -1:00PM

Working lunch

1:00PM -2:05PM

Session 22: CAR-T in AML
Chairs: Saar Gill & David Sallman                                                                                                                         

  • AML targets/translational updates: Fabiana Perna
  • Current status of CAR-T therapies in AML/MDS: David Sallman
  • Mechanism of resistance in AML: Anand Bhagwat
  • CAR-T in pediatric AML: Nirali Shah
  • Optimizing and future directions with CAR-T/NK therapies in AML: Naval Daver

Panel discussion

2:05PM -2:10PM

Conclusions and end of meeting